Cantor Fitzgerald reissued their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $58.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com initiated coverage on Xenon Pharmaceuticals in […]
Cantor Fitzgerald reaffirmed their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $58.00 price target on the biopharmaceutical company’s stock. XENE has been the topic of several other research reports. Stifel Nicolaus lifted their price target […]
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Analyst Upgrades and Downgrades A number of analysts have recently issued reports […]
Knott David M Jr lessened its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 32.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,000 shares of the biopharmaceutical company’s stock after selling 19,500 shares during the quarter. Knott David M […]
StockNews.com assumed coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other analysts have also commented on XENE. Cantor Fitzgerald assumed coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, April […]